TAT 2017
Poster sessions

Poster session 1: Biomarkers

P1.1 Mass spectrometric quantitation of TUBB3 may predict response to docetaxel in patients with gastric cancer
Dr. Cecchi, NantOmics, Rockville, MD, United States

P1.2 Identification of gene signatures in the tumor microenvironment correlating with clinical responses to the intratumorally injected TLR4 agonist G100
Dr. Paya, Immune Design, South San Francisco, California, United States

P1.3 The association between tumor MHC class I expression and density of tumor-infiltrating immune cells and prognosis in resected uterine cervical adenocarcinoma.
Dr. Kawai, National Cancer Center Hospital, Tokyo, Japan

P1.4 Elevation of glucose transporter regulates the invasiveness of colorectal cancer
Mr. Kuo, Taipei medical university, Taipei, Taiwan


Poster session 2: Drug design

P2.1 Efficient production of bispecific antibodies by orthogonal Fab interface engineering
Dr. Desjardins, Zymeworks Inc., Vancouver, British Columbia, Canada

P2.2 New ifosfamide analogs for immunotherapy and nanomedicine against cancer
Miss. Delahousse, Vectorology and Anticancer Therapies, UMR CNRS 8203, Gustave Roussy, Université Paris-Saclay and Pharmacology and Drug Analysis Department, Gustave Roussy, Villejuif, France


Poster session 3: Molecular profiling and diagnosis

P3.1 MET aberrations across multiple tumor types: Results from the prospective MOSCATO-01 trial
Dr. El-Dakdouki, Gustave Roussy, Villejuif, France

P3.2 Defining ATMicity with transcriptome profiling in non-small cell lung cancer (NSCLC)
Dr. Bebb, Univeristy of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada

P3.3 Investigating the role of circulating tumor cells (CTC) in biliary tract cancer (BTC)
Dr. Cappelletti, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milano, Italy


Poster session 4: New molecular targets

P4.1 Caspases/NOX2 axis: a potential target to modulate macrophage polarization
Dr. Solier, Gustave Roussy, Villejuif, France

P4.2 Potentiation of targeted breast cancer therapy through CDK8/19 inhibition
Prof. Dr. Broude, University of South Carolina, Columbia, SC, United States

P4.3 Targeting of cancer cells by induction of differentiation of cancer stem cells into non-proliferating cells
Mr. Shah, Université Paris Diderot - Paris 7, Paris, France

P4.5 Elevation of Yes-associated protein (YAP) promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer
Mr. Ling, Taipei Medical University, Taipei, Taiwan

P4.6 MafB inhibits tumor growth through regulating the population of tumor-associated macrophages
Ms. Imamura, University of Tsukuba, Japan, Tsukuba, Ibaragi, Japan


Poster session 5: Phase 1 studies

P5.1 A first-in-human Phase I/II, dose escalation, pharmacokinetic study to assess safety and tolerability of VAL201 in advanced prostate cancer
Dr. Kristeleit, Cancer Institute, University College London, London, United Kingdom

P5.3 Preliminary efficacy of the natural killer cell–targeted antibody lirilumab plus nivolumab in squamous cell carcinoma of the head and neck
Dr. Even, Institut Gustave Roussy, Villejuif, France

P5.4 Phase I clinical trials for bile tract cancer
Dr. Koyama, National Cancer Center Hospital, Tokyo, Japan

P5.5 Comparison of adverse events beyond cycle 1 between cytotoxic combination and molecularly targeted phase I trials
Miss. Jordan, King's College London, London, United Kingdom

P5.6 Timings of severe toxicity of cytotoxic drugs and molecularly-targeted drugs in phase I trials: a single-institution experience in Japan.
Dr. Sudo, National Cancer Center Hospital, Tokyo, Japan


Poster session 6: Clinical studies (non-phase 1)

P6.1 A Phase II Trial of cabozantinib (XL184) in metastatic refractory soft tissue sarcoma
Dr. Meehan, National Institute of Health/National Cancer Institute, Bethesda, Maryland, United States

P6.2 Phase II study of FOLFOX and bevacizumab with the autophagy inhibitor hydroxychloroquine in metastatic colorectal adenocarcinoma
Dr. O'Hara, University of Pennsylvania, Philadelphia, PA, United States

P6.3 Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?
Prof. de Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy


Poster session 7: Preclinical drug profiling & test models

P7.1 PF-114, new selective inhibitor of Bcr-Abl tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells
Prof. Shtil, Blokhin Cancer Center, Moscow, Russia

P7.2 Use of 3D spheroid cultures to screen for drugs targeting cancer stem cells
Dr. Prieto, StemTek Therapeutics, Derio, Vizcaya, Spain

P7.3 NPT-001 – a new selective inhibitor of the anaplastic lymphoma kinase: differential molecular mechanisms of cytotoxicity
Dr. Tatarskiy, Blokhin Cancer Center, Moscow, Russia

P7.4 Loss of Axin1 drives acquired resistance to WNT pathway blockade in colorectal cancers cells carrying RSPO3 fusions
Dr. Torchiaro, Candiolo Cancer Institute – FPO IRCCS, Turin, Italy

P7.5 Targeting N-Myc-amplified neuroendocrine tumors with the aurora kinase inhibitor, danusertib
Drs. Carpinelli, Nerviano Medical Sciences, srl, Nerviano, Italy

P7.6 Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer (NSCLC) cells
Mrs. Noor, Vrije Universiteit Brussels, Brussels, Belgium

P7.7 PEGylated TRAIL for carcinogen-induced colorectal cancer therapy
Prof. Dr. Lee, SungKyunKwan University, Suwon City, South Korea

P7.8 Panobinostat sensitizes KRAS-mutant non-small cell lung cancer to gefitinib by targeting tafazzin (TAZ)
Mr. Lin, Taipei Medical University, Taipei, Taiwan

P7.9 α-Terthienylmethanol induces S phase cell cycle arrest by inducing ROS stress in human ovarian cancer cells
Ms. Preya, Division of Molecular Biology, Seoul, South Korea

P7.10 Bacillus arginase and dichloroacetate act synergistically to enhance cytotoxic and anti-proliferative effects in breast cancer cells
Dr. Verma, University of Macau, Macau, Macau

P7.11 Suppression of triple-negative breast cancer by pan-histone deacetylase inhibitor panobinostat through targeting Yes-associated protein (YAP)
Mr. Cheng, Taipei Medical University, Taipei, Taiwan


Poster session 8: Targeted drug delivery

P8.3 Drug-release controlling effects via intramembranous radical pair model induced by homogeneous magnetic fields
Dr. Nakagawa, Tokyo Denki University, Tokyo, Japan

P8.4 Click-apoptin as novel strategy to generate homogeneous tumor targeted weapons
Ms. Niesler, Charité – Universitätsmedizin Berlin, Institut für Laboratoriumsmedizin, Klinische Chemie und Pathobiochemie; Berlin Institute of Health (BIH), Berlin, Germany

P8.6 A novel tool to generate highly defined immunotoxins: clickable dianthin
Trautner, Charité – Universitätsmedizin Berlin, Berlin, Germany


Poster session 9: Translational studies

P9.1 Evaluation of the response to immunotherapy agents in previously irradiated fields
Dr. Menis, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France

P9.2 Type II RAF inhibition causes superior ERK suppression versus type I RAF inhibition in several BRAF mutants recurrently found in lung cancer
Mr. Giron, Vrije Universiteit Brussel, Brussels, Belgium

P9.3 Novel pan-ERBB cancer therapeutic
Prof. Dr. Schroeder, Alliance Therapeutics, Tucson, Arizona, United States

P9.4 Rigosertib as a radio-sensitizer for concurrent chemo-radiation treatment of cholangiocarcinoma (CCA): a comparative study in vitro
Dr. Damian, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

P9.6 Estrogen-dependent changes in intracellular iron status precipitate anticarcinogenic effects in MCF-7 breast cancer cells
Prof. Hamad, University of Sharjah, Sharjah, United Arab Emirates

P9.7 A lung cancer-derived CRAF mutation is ERK pathway activating and predicts sensitivity to LY3009120 and trametinib
Mr. Noeparast, Vrije Universiteit Brussel, Brussels, Belgium

Poster session 10: Late breaking abstracts

P10.1 Intratumoral heterogeneity and tumor-host crosstalk alter drug sensitivity of clonal subpopulations
Dr. Wellstein, Georgetown University, Washington, DC, United States

P10.2 Vascular targeted photodynamic therapy for cancer treatment; optimization and dose control
Dr. Goldschmidt, Weizmann Institute of Science, Rehovot, Israel